Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca and Incyte to conduct new lung cancer clinical trial

AstraZeneca and Incyte to conduct new lung cancer clinical trial

13th January 2016

AstraZeneca is expanding its partnership with Incyte to launch a new lung cancer clinical trial collaboration.

The new collaboration will evaluate the efficacy and safety of Incyte's Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in combination with AstraZeneca's next generation epidermal growth factor receptor (EGFR) inhibitor Tagrisso.

Together, the therapies will be assessed as a second-line treatment for patients with EGFR mutation-positive non-small cell lung cancer who have been treated with a first-generation EGFR tyrosine kinase inhibitor and subsequently developed the T790M resistance mutation.

A phase I/II study will be conducted by Incyte, with the phase I part of the trial expected to establish a recommended dose regimen, while the phase II portion will assess the therapy's safety and efficacy profile.

Antoine Yver, head of oncology for global medicines development at AstraZeneca, said: "We are pleased to be building on our existing relationship with Incyte and exploring a potentially exciting combination for lung cancer patients who have developed a resistance to first-generation EGFR inhibitor treatment."

The company also recently announced that it will be carrying out secretome-oriented research as part of a new study collaboration with the Wallenberg Centre for Protein Research.ADNFCR-8000103-ID-801809909-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.